![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » IMV Selects COVID-19 Vaccine Candidate for Human Trials
IMV Selects COVID-19 Vaccine Candidate for Human Trials
![IMV_Logo-430x250.png](https://www.fdanews.com/ext/resources/test/Drug-Images4/IMV_Logo-430x250.png?t=1590461093&width=430)
Canadian biopharmaceutical firm IMV has selected a COVID-19 vaccine candidate, DPX-COVID-19, that it will advance to human trials this summer.
The vaccine is a DPX-based formulation of multiple peptides of SARS-CoV-2 that generated strong immune responses at the preclinical stage. The vaccine is fully synthetic, so it has the potential for rapid and large-scale manufacturing.
IMV expects to initiate a phase 1 trial testing the vaccine in 84 healthy volunteers this summer.
Upcoming Events
-
18Jul
-
21Oct